Flerie Writes Off Its Obesity Drug Just as the Market Pays Up for Obesity

A SEK 230m Empros mark-to-zero becomes a pivot toward muscle-sparing metabolic science — funded 8.1x by other people's money.

FLERIE.ST · Earnings Call · 2026-10-15

A holding company's quarter is a list of valuation events

Flerie AB is not a drug developer; it is a Nordic life-science investor that marks portfolio companies to fair value. Its quarterly result is therefore less an operating print than a ledger of repricings — and Q3 2026 delivered a painful one: a SEK 230 million mark-to-zero on Empros Pharma. CFO Cecilia Stureborg von Schéele put NAV at SEK 3.1 billion, or SEK 35.91 per share, with 87% of that value locked in private companies. Total portfolio value fell SEK 249 million in the quarter — SEK 221 million inside product development and SEK 28 million in commercial growth. The valuation machinery is itself the story. Public holdings are marked to market instantly; private ones sit at the last completed funding round. Bad news bites NAV immediately, good news lags. “we do not continuously increase values just based on our own assessment of the company's potential or progress” — Cecilia Stureborg von Schéele, CFO · 2026-10-15, the CFO explained. That asymmetry is why Empros went straight to zero while Microbiotica's fresh financing added only SEK 27 million. It also means the headline NAV under-reports clinical progress that management insists is real.

The paradox: killing an obesity asset while obesity rallies

Here is the tension worth holding on to. Flerie just buried a weight loss drug at the very moment the tape is rewarding obesity. The global 30- and 90-day movers include patients with obesity names like REGN, NVO and VKTX, and oral GLP 1 names like LLY, AZN and MDGL. Flerie is not disagreeing with that wave — it is conceding it. Empros was squarely in the weight-loss lane, and CEO Ted Fjällman is unsparing about why the company walked away: “there just is not a commercial space, and you just cannot compete with the GLP-1s at this point in time” — Ted Fjällman, CEO · 2026-10-15. With no partner willing to fund Phase III, the option was to spend its own capital on a me-too mechanism — and it chose not to. What replaces it is the genuinely new theme. Atrogi's ATR-258 targets the quality of weight loss rather than the quantity, and Fjällman's framing is the differentiator the field is chasing:

those who are in the field realize that it is quality of weight loss, i.e. preservation of muscles while reducing fat that is the important issue. Long-term improved physical function is pivotal... they are really looking for ways to spare muscle loss while still reducing fat.
Ted Fjällman, CEO · 2026-10-15

The keyword history makes the shift visible. muscle and muscle mass appear as fresh top movers for Flerie this quarter, sitting alongside GLP-1. The company is riding the same obesity wave everyone else is — but repricing its exposure from the crowded fat-loss lane into the muscle-sparing niche. Fjällman calls the early Atrogi readout, at a high level, “fat down, muscle up, but also function up” — Ted Fjällman, CEO · 2026-10-15, and explicitly frames it as Atrogi being positioned for the next wave of partnering. That is where he wants to place shareholders' money.

Nothing broke in the funding engine

The reason a single-asset disaster is survivable is the syndication model, and this is the part of the quarter that actually got better, not worse. Flerie deployed SEK 127 million in follow-ons; other investors put in more than eight times that. In product development, external investors contributed SEK 9.2 for every SEK Flerie invested; in commercial growth, the ratio was 150x. Fjällman's summary: “8.1x more money was invested by others into our portfolio than we did. There were over SEK 1 billion invested in Q3 into our companies” — Ted Fjällman, CEO · 2026-10-15. That distinction matters enormously. Empros is a company-specific clinical and commercial event, not a crack in Flerie's ability to attract co-investors. The other moving pieces reinforce the point: Xspray took a complete response letter and a SEK 35 million hit, but the contract manufacturer's Italian site issue has been resolved; Egetis was sold out entirely, which management counted as a win; and the Biosergen take-private is set to register on October 23, delivering a Phase II-ready antifungal asset for a net SEK 10 million after the cash that comes with it.

The mechanic nobody prices: a value transfer, not just a dilution

One under-covered thread from the quarter is the share-count maneuver. A bonus issue in May added 12 million shares; the majority shareholder then voluntarily returned his, and 8.5 million were cancelled, leaving 3.5 million net new shares. NAV per share fell roughly SEK 1.5 from April to June — but, as the CFO noted, almost SEK 100 million of value moved from the majority holder to the minorities in the process. For a small-cap trading near SEK 35 NAV, that is a governance signal disguised as a dilution headline, and it says something about alignment that management barely lingered on. The forward catalysts are concrete: Xspray resubmission and a new PDUFA date hoped for before year-end, Symcel's caloTrace commercial launch, AnaCardio starting Phase IIb after a EUR 62.5 million round led by Novo Holdings, and CAR Medical and Prokarium data in the first half of 2027. Whether any of this shows up in NAV depends on the private-marking lag Fjällman keeps flagging. The real question is whether Flerie's NAV is a rear-view mirror. It wrote off the asset that GLP-1 made uninvestable and doubled toward the one the market is only beginning to value — muscle preservation — funded almost entirely by other people's capital. That is either disciplined concentration or a portfolio drifting away from what was supposed to be its differentiator. This quarter, at least, it is a strategic pivot with a clear rationale and a tape that agrees with the direction.